FDMT - per Saturday PR: 4D Molecular Therapeutics' 4D-150 Achieves 78% Overall Treatment Burden Reduction At 2 Years, With 87% Reduction In
FDMT - per Saturday PR: 4D Molecular Therapeutics' 4D-150 Achieves 78% Overall Treatment Burden Reduction At 2 Years, With 87% Reduction In Recently Diagnosed Wet Age-Related Macular Degeneration Subgroup
FDMT - per Saturday PR: 4D Molecular Therapeutics' 4D-150 Achieves 78% Overall Treatment Burden Reduction At 2 Years, With 87% Reduction In Recently Diagnosed Wet Age-Related Macular Degeneration Subgroup